Aircraft Designer CubCrafters Inc. Expands Investment Options

 

• Backcountry aviation innovator CubCrafters is advancing its ability to respond to customers of its popular XCub and other aircraft products by welcoming outside investors
• CubCrafters’ public investment offering was initially introduced last year through a Reg A+ filing qualified by the FTC in November, at which point more than $26 million of its $50 million goal had already been reserved pre-offering
• The company announced Jan. 17 that it has expanded that investment opportunity to residents in Florida, New Jersey, Texas, and Washington, through a Regulation CF campaign serving non-accredited investors who couldn’t qualify under the Reg A+ program
• Both investment offerings offer the same terms — $5 per share and a minimum investment of $400

The introduction of a new Regulation CF campaign by Yakima, Wash.-based aviation company CubCrafters has helped the best-in-class backcountry aircraft producer clear a critical hurdle to accepting investments from non-accredited investors in several states as a result of local restrictions in those states.

The allowance for investment from non-accredited investors living in Florida, New Jersey, Texas and Washington means it is now possible for investors in every state to participate in CubCrafters’ public offering if they wish.

“Our fans, customers, aviation enthusiasts, employees, and even the general public in the states of Florida, New Jersey, Texas, and Washington have told us that they very much want to participate in this investment opportunity,” CubCrafters President and CEO Patrick Horgan stated in the company’s news release (https://nnw.fm/Y9lHJ). “It was always our intention for everyone to be able to participate in our offering regardless of their location, and now they can.”

CubCrafters unveiled its plans to become a publicly funded company in July with an announcement that it would accept reservations for preferred stock under a Reg A+ filing, and in November Horgan announced the Federal Trade Commission (“FTC”) qualified the Reg A+ filing, opening the door for the investors to come onboard (https://nnw.fm/1cR77).

The new Regulation CF campaign offers the same terms for preferred stock to the public — an initial price of $5 per share and a minimum investment of $400, according to the company.

The company aims to raise up to $50 million and had already received reservations for more than $26 million of its shares within 90 days of its announcement it would accept outside investment for the first time.

CubCrafters builds popular FAA-certified aircraft, light sport airplanes that meet international air traffic flow management (“ATFM”) standards, experimental aircraft for hands-on builders taking advantage of the company’s assistance program, and kits for those prepared to work on their own. 

The purpose of the funding drive is to help the company grow sufficiently that it can reduce customers’ wait times (currently booked out at about two years) while also enabling the company to accelerate the pace of innovation to develop faster, more powerful, technically capable aircraft, to improve customer support, and to boost sales in overseas markets where the company flagship XCub aircraft has received international certifications.

Its XCub and Carbon Cub SS models are advanced versions of the legacy Super Cub using current-day technology — a high-performance fixed-wing craft useful for accessing backcountry areas without the need for paved runways, whether for commercial needs or for personal recreation.

The airplanes have lower operational costs than helicopters, which have also made them attractive to the government, leading to a contract with the U.S. Department of Agriculture announced last month to replace some of its aging Piper PA-18 Super Cubs currently in its fleet.

“Our goal here at CubCrafters is to provide them with such a good platform (an aircraft that is more capable, more cost effective, and safer), that they ultimately replace their entire current fleet of around 40 legacy aircraft with the XCub,” Vice President of Sales and Marketing Brad Damm told Flying magazine (https://nnw.fm/Gsybh).

For more information, visit the company’s website at www.CubCrafters.com.

NOTE TO INVESTORS: The latest news and updates relating to CubCrafters Inc. are available in the company’s newsroom at https://nnw.fm/CUB

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

MetAlert, Inc. (MLRT) Planned Acquisition of TrakTec LLC Adds Superior Radio Frequency-Based Tracking Technology to Portfolio of Location-Based Solutions

 

• MetAlert recently announced the planned acquisition of TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications
• The acquisition is expected to add several products to MetAlert’s existing suite of products, one of which is an RFID and Bluetooth-enabled tracking technology called SafetyNet(R)
• The SafetyNet Tracking System comprises the SafetyNet Bracelets that patients wear, and a receiver-antenna combo used by police departments and first responders
• The Chelmsford Police Department in Massachusetts recently reported it had successfully located a missing senior citizen with dementia because of its participation in the SafetyNet program
• The department has, over time, established that radio frequency can be superior to GPS at successfully tracking missing persons, especially in challenging conditions such as densely wooded areas, buildings, basements, and shallow water

MetAlert (OTC: MLRT), a pioneer in smart, mobile, and wearable GPS tracking and recovery location-based products and services, is implementing a solid growth strategy that has seen it enter into a Heads of Terms agreement to acquire TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications. Announced January 11, the agreement is expected to close on or before March 17 this year upon completing satisfactory due diligence and audits (https://nnw.fm/4YlSw).

The acquisition is expected to add iGPS products, namely the Wizard GPS Tracking Watch Phone for children and the Phoenix GPS-based smartwatch for seniors, and SafetyNet(R), a radio-frequency identification (“RFID”) and Bluetooth-enabled tracking technology, to MetAlert’s existing suite of mostly GPS-based tracking products. Of the additions, SafetyNet stands out because of radio frequency’s unique advantages over GPS in certain outdoor environments.

TrakTec’s SafetyNet System comprises bracelets designed to be worn on the wrist or ankles at all times and individually emit a unique signal that represents the wearable’s own RFID. It is this RFID that is then fed into a receiver to enable tracking. The receivers are meant to be operated by law enforcement officials as part of the SafetyNet Tracking Systems program, with the police departments receiving handheld and vehicle-mounted antennas that isolate and boost the RF produced by the bracelets. Generally, the SafetyNet Tracking System is intended to help public safety agencies quickly locate patients with such conditions as autism, Alzheimer’s disease, and dementia.

Once an alert goes out that a SafetyNet user is missing, the first responders whose vehicle is equipped with an antennae head to the missing person’s last known location. This antenna, which isolates the incoming signals from the bracelet, allows the responders to track the location of the missing person up to a proximity of about a quarter of a mile, at which point the responders shift to the handheld tracking device that has a directional antenna. This device enables the responders to further isolate the person’s location and eventually find them.

Since its formation in 2010, SafetyNet has been deployed in more than 1,000 rescue cases (https://nnw.fm/DoxxC) and is utilized by police departments across more than 15 US states (https://nnw.fm/WhQAr). One of these departments, the Chelmsford Police Department in Massachusetts, recently reported successfully locating a missing senior citizen with dementia because of its participation in the SafetyNet program (https://nnw.fm/ixPtO).

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://nnw.fm/MLRT

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial

 

• SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation
• Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions
• Data collection from all study groups expected by April 2023
• SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company that fuses traditional medicine with psychedelics, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation.

Research into psychedelics like psilocybin has recently experienced a renaissance, specifically for treating depression, addiction, anxiety, obsessive-compulsive disorder, and inflammatory diseases (https://nnw.fm/APQlC). Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar disorder, and chronic pain.

“The UCSF research team is making progress on the clinical trial,” said Eric Weisblum, Chief Executive Officer of Silo Pharma (https://nnw.fm/UblCB). “The data gathered from these studies could uncover the role of inflammatory activity on such conditions as Parkinson’s, bipolar disorder, and chronic pain. Utilizing psilocybin in this study in a regimented dosing pattern, we hope to gain significant data both in mechanism of action and potential biomarker for personalization of psilocybin therapy.  The targeted patient populations from the study could provide support for the development and use of psilocybin as a therapeutic coupled with our novel homing peptides and topical technology.”

The clinical study comprises preparation therapy, two separate dosing sessions with psilocybin, and integration therapy for the three patient populations afflicted with Parkinson’s disease, bipolar disorder, and chronic pain. Blood samples are collected from each patient at four points: one at baseline before treatment begins, one at 24 hours following both dosing sessions, and one after 30 days during a follow-up session. Data collection from the study is expected to be completed by April 2023 for all three patient populations.

In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a joint partnership agreement with Columbia University (https://nnw.fm/jAcVh). The company initially entered a sponsored pact with the university in October 2021 and has recently extended the contract to continue research for SPC-14 and SPC-15, a targeted therapeutic for stress-induced anxiety disorders (https://nnw.fm/Mmezs).

Silo Pharma Inc. is fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, and other rare neurological disorders. The company partners with leading institutions such as Columbia University, the University of California San Francisco (“UCSF”), and the University of Maryland, Baltimore (“UMB”) to develop treatments the company believes will transform healthcare and improve patient outcomes.

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://nnw.fm/SILO

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

SideChannel Inc. (SDCH) to Provide Key Operational Updates and Strategic Priorities During Investor Day Virtual Event on February 15, 2023

 

• The February 15, 2023 Investor Day virtual event will be hosted by the company’s President and CEO, Brian Haugli, and CFO, Ryan Polk
• Reports have shown an increase in cyberattacks due to the growth in network attack surfaces for in-office and remote workers who rely on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business
• SideChannel’s newest product release, Enclave(TM), is a comprehensive cloud and network solution that enables IT teams to contain breaches faster, reduce network outages, minimize latency, and strengthen overall defensive security

SideChannel (OTCQB: SDCH), a provider of cybersecurity services and technology, develops technologies to make cybersecurity simple and accessible, by matching organizations worldwide with expert virtual Chief Information Security Officers (vCISOs), allowing companies to assess cyber risk and ensure cybersecurity compliance, without jeopardizing financial assets. The company has announced its Investor Day event to be held virtually on February 15, 2023, from 9:00 am to 10:30 am EST (https://nnw.fm/ZYEvb).

Investor Day will be hosted by SideChannel’s President and CEO, Brian Haugli, and CFO, Ryan Polk, who will provide updates on the Company’s operations, recent developments, and strategic priorities. SideChannel will accept questions from investors via email before the event, which can be submitted to ir@sidechannel.com. Investors planning to attend SideChannel’s Investor Day event will need to preregister for the event by filling out an online form (https://nnw.fm/6Qiz3).

SideChannel is committed to creating top-tier cybersecurity programs for small and mid-sized businesses, helping them protect their data and assets, and has created over 50 multi-layered cybersecurity programs for clients. The company lends its talents to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for growing enterprises.

Reports have shown that cyberattacks on these types of businesses have increased in recent years due to the exponential growth of network attack surfaces. More remote and in-office workers rely on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business. With this in mind, SideChannel is continually expanding its service offerings, workforce, and customer base – attracting over 20 vCISOs to serve across a vast number of industries, including fintech, biotech, healthcare, manufacturing, legal, defense, and technology services.

SideChannel’s recent product offering includes Enclave(TM), a comprehensive cloud and network solution that enables IT teams to contain breaches faster, reduce network outages, minimize latency, and strengthen overall security defense. Enclave creates the foundation for a zero-trust network security model that IT can build upon, segmenting a company’s network to organize personnel and computing devices at the employee level and implement security controls across all network segments.

The cybersecurity market is projected to reach $173.5 billion by the end of 2023, with security services anticipated to be the largest segment valued at $91.21 billion. The average spend per employee in the cybersecurity market is projected to reach $8,190 in 2023. The market is expected to grow at a CAGR of 10.9%, resulting in a revenue volume of $262.4 billion by 2027. Compared to global revenue, the United States is expected to account for approximately $69.7 million in 2023 (https://nnw.fm/YqlHR).

Enclave was designed and purpose-built to serve the growing security needs of small to mid-sized organizations. This traditionally underserved market is more prone to cyber-attacks but has limited protection due to smaller budgets, inadequate IT security staffing, and a lack of cybersecurity awareness among top executives. SideChannel’s product is affordable and effective – shrinking the attack surface area exposed to cyber intruders and significantly reducing the effort required to operate securely.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://nnw.fm/SDCH

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

 

• Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability
• Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract
• Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with the speed of onset, and brain absorption. Lexaria is focusing ongoing research and development efforts on the advancement of product candidates across several key segments, including, nicotine replacement, CBD, cardiovascular drugs, antivirals, epilepsy, human hormones, and PDE5 inhibitors.

Bioavailability measures how much of a substance enters the bloodstream, with intravenous administration being the most effective approach to 100% bioavailability for maximum effect. While oral administration is less intrusive and preferred, it presents less efficacy and bioavailability of APIs due to obstacles like gut disorders and stomach acid and liver biotransformation.

Although Lexaria is focused on pharmaceutical bioavailability, it’s interesting to note that bioavailability even plays a role in nutrition. While macronutrients (carbs and fat) offer higher levels of bioavailability – micronutrients, commonly sold as supplements (vitamins, minerals, flavonoids, and carotenoids), can be harder for the body to absorb. Studies show that not all the nutrients we eat enter the bloodstream after entering the digestive tract. Some factors that affect bioavailability include where the food is grown or made, when it was harvested, how it was prepared, the foods you eat with it, and highly individualized physiological traits that affect how your body processes that food.

With studies showing that around 40% of available drugs are poorly bioavailable (https://nnw.fm/89I8F), the determined factors that affect drug bioavailability include:

• The size of the drug’s molecule
• The type of drug administered
• The amount of food eaten
• The time of day the drug is taken

Understanding the bioavailability of a drug is crucial for clinicians looking for appropriate routes of administration and schedule for drug delivery. Lexaria is investigating its DehydraTECH technology for increased bioavailability of APIs with epilepsy, high blood pressure, dementia, diabetes, and more.

The global pharmaceutical drug delivery market is projected to reach $2.21 billion by 2026, growing with a CAGR of 5.9% from a value of $1.66 billion in 2021. Growth is highly attributed to factors including the rising prevalence of chronic diseases, the growing biologics market, increased R&D investments, and technological advancements, which include new product launches (https://nnw.fm/kKhlw). 

Animal studies have also demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery. Since 2016, Lexaria’s technology has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reduce the onset time from one to two hours to just minutes, and mask unwanted tastes.

The company’s recent study, EPIL-A21-1, demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). The study’s results have demonstrated the performance of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and, in some cases, even surpass the performance of Epidiolex. The findings from the study further support Lexaria’s efforts and clinical trials, which are currently being explored for other indications, including hypertension, dementia, and diabetes. The indications explored by Lexaria are chosen due to their current underserved medical needs, as DehydraTECH helps enhance bioavailability of substances for treatment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork